Hillhouse Capital Management, Ltd.
Insider CIK 1510589 · APLS 10% owner · BGNE 10% owner · AVBP 10% owner · ENFN 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma, Inc. | S Sale | 2025-12-10 | 2026-02-03 | 555,555 | $23.37 | $12.98M | 3,929,117 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2024-12-02 | 2024-12-04 | 17,842,500 | $200.00 | $3.57B | 125,045,741 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion deriv | 2024-01-30 | 2024-02-01 | 4,761,903 | — | $0 | 0 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion deriv | 2024-01-30 | 2024-02-01 | 55,000,000 | — | $0 | 0 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion | 2024-01-30 | 2024-02-01 | 3,616,041 | — | $0 | 3,616,041 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | P Buy | 2024-01-30 | 2024-02-01 | 555,555 | $18.00 | $10.00M | 4,484,672 | SEC↗ |
| AVBP ArriVent Biopharma, Inc. | C Conversion | 2024-01-30 | 2024-02-01 | 313,076 | — | $0 | 3,929,117 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2023-06-14 | 2023-06-15 | 273,728 | $207.72 | $56.86M | 142,888,241 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2023-06-13 | 2023-06-15 | 611,000 | $211.45 | $129.20M | 143,475,369 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2023-06-13 | 2023-06-15 | 313,400 | $128.43 | $40.25M | 143,161,969 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2023-06-12 | 2023-06-12 | 968,812 | $213.91 | $207.24M | 144,086,369 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2023-06-12 | 2023-06-12 | 281,400 | $130.83 | $36.82M | 145,055,181 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2023-06-09 | 2023-06-12 | 328,952 | $217.02 | $71.39M | 145,336,581 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2023-06-09 | 2023-06-12 | 213,700 | $130.35 | $27.86M | 145,665,533 | SEC↗ |
| BGNE BeiGene, Ltd. | S Sale | 2023-06-08 | 2023-06-12 | 1,163,825 | $218.14 | $253.88M | 145,879,233 | SEC↗ |
| BGNE BeiGene, Ltd. | J Other | 2022-08-22 | 2022-08-24 | 7,800 | — | $0 | 147,043,058 | SEC↗ |
| ENFN Enfusion, Inc. | S Sale | 2021-10-25 | 2021-10-27 | 647,862 | $15.90 | $10.30M | 4,975,183 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion deriv | 2017-11-13 | 2017-11-15 | 4,476,275 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | C Conversion | 2017-11-13 | 2017-11-15 | 2,098,581 | — | $0 | 2,098,581 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | P Buy | 2017-11-13 | 2017-11-15 | 1,428,571 | $14.00 | $20.00M | 3,527,152 | SEC↗ |
| BGNE BeiGene, Ltd. | C Conversion deriv | 2016-02-08 | 2016-02-10 | 15,811,965 | — | $0 | 0 | SEC↗ |
| BGNE BeiGene, Ltd. | C Conversion deriv | 2016-02-08 | 2016-02-10 | 14,814,814 | — | $0 | 0 | SEC↗ |
| BGNE BeiGene, Ltd. | C Conversion | 2016-02-08 | 2016-02-10 | 30,626,779 | — | $0 | 30,626,779 | SEC↗ |
| BGNE BeiGene, Ltd. | P Buy | 2016-02-08 | 2016-02-10 | 9,100,000 | — | $0 | 39,726,779 | SEC↗ |